Stock Events

Stock Events

Abivax 

€97.45
140
-€0.35-0.36% Monday 15:29

Statistics

Day High
100.8
Day Low
97.35
52W High
137.4
52W Low
60.85
Volume
1,706
Avg. Volume
-
Mkt Cap
8.5B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

21SepExpected
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Next
-2.1
-1.6
-1.1
-0.61
Expected EPS
-0.82439766641597
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-336.1MNet Income

Analyst Ratings

117.02Average Price Target
The highest estimate is 141.90.
From 9 ratings within the last 6 months. This is not an investment recommendation.
Buy
78%
Hold
22%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 2X1.XETRA. It's not an investment recommendation.
TotalEnergies
26
TTE.PA
Air Liquide
25
AI.PA
NVIDIA
20
NVDA
Lvmh Moet Hennessy Louis Vuitton
17
MC.PA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap187.23B
Gilead Sciences is a biopharmaceutical company that competes with Abivax in the development of antiviral drugs, including treatments for HIV, which is a focus area for Abivax.
Vertex Pharmaceuticals
VRTX
Mkt Cap138.42B
Vertex Pharmaceuticals is involved in creating antiviral treatments and therapies for infectious diseases, competing directly with Abivax's efforts in HIV and other viral infections.
Merck
MRK
Mkt Cap370.89B
Merck & Co., Inc. is a global healthcare company that develops antiviral drugs, including therapies for HIV/AIDS, positioning it as a competitor to Abivax.
GSK
GSK
Mkt Cap99.96B
GlaxoSmithKline plc focuses on developing and marketing vaccines and medications for HIV, directly competing with Abivax's research and development in HIV treatments.
Johnson & Johnson
JNJ
Mkt Cap663.28B
Johnson & Johnson, through its pharmaceutical division Janssen, works on developing treatments for infectious diseases, including HIV, making it a competitor to Abivax.
Abbvie
ABBV
Mkt Cap453.19B
AbbVie Inc. competes in the area of antiviral research, with a focus on therapies for HIV, hepatitis, and other viral infections, areas that Abivax is also targeting.
Pfizer
PFE
Mkt Cap162.16B
Pfizer Inc. is involved in the discovery, development, and manufacture of healthcare products, including antiviral drugs, competing with Abivax in the infectious disease space.
Bristol-Myers Squibb
BMY
Mkt Cap136.49B
Bristol Myers Squibb is engaged in the discovery and development of prescription medicines for various diseases, including HIV/AIDS, making it a direct competitor to Abivax.
Regeneron Pharmaceuticals
REGN
Mkt Cap85.22B
Regeneron Pharmaceuticals, Inc. is known for its work in biotechnology and the development of medicines for infectious diseases, competing with Abivax in the biopharmaceutical field.
Novartis
NVS
Mkt Cap304.1B
Novartis AG is a global healthcare company that researches and develops treatments for a wide range of diseases, including viral infections, competing with Abivax in the pharmaceutical and healthcare market.

About

Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. The company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD. The Group operates in a single operating segment: R&D of pharmaceutical products in order to market them in the future.
Show more...
CEO
Marc de Garidel
Employees
69
Country
France
ISIN
FR0012333284
WKN
000A14UQC

Listings

F
DE
2X10.F
STU
DE
2X10.STU
XETRA
DE
2X1.XETRA
STU
DE
2X1.STU

0 Comments

Share your thoughts

FAQ

What is Abivax stock price today?▼
The current price of 2X1.XETRA is €97.45 EUR — it has decreased by -0.36% in the past 24 hours. Watch Abivax stock price performance more closely on the chart.
What is Abivax stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XETRA Stock Exchange exchange Abivax stocks are traded under the ticker 2X1.XETRA.
What is Abivax market cap?▼
Today Abivax has the market capitalization of 8.5B
When is the next Abivax earnings date?▼
Abivax is going to release the next earnings report on September 21, 2026.
What were Abivax earnings last quarter?▼
2X1.XETRA earnings for the last quarter are -0.61 EUR per share, whereas the estimation was -0.8 EUR resulting in a +24.01% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Abivax revenue for the last year?▼
Abivax revenue for the last year amounts to 0 EUR.
What is Abivax net income for the last year?▼
2X1.XETRA net income for the last year is -336.1M EUR.
How many employees does Abivax have?▼
As of September 08, 2026, the company has 69 employees.
In which sector is Abivax located?▼
Abivax operates in the Health & Wellness sector.
When did Abivax complete a stock split?▼
Abivax has not had any recent stock splits.
Where is Abivax headquartered?▼
Abivax is headquartered in Paris, France.